Clinical Trials
6 trialsNCT02595424 2026-05-01
Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT01824875 2026-02-25
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT01525082 2024-02-06
Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors
Stanford University
Phase 2 Completed
NCT03930771 2022-08-09
TMZ-Cap
Weill Medical College of Cornell University
Phase 2 Terminated
NCT00398320 2017-03-01
Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors
Stanford University
Phase 2 Completed
NCT00869050 2016-07-25
Capecitabine and Temozolomide for Neuroendocrine Cancers
Columbia University
Phase 2 Completed